SCHEMBL29937865

SCHEMBL29937865

CS(=O)(=O)C1CN(C2CCC(c3nc(N)c4ccccc4n3)CC2)C1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GBA1 P04062 1/20 0.42
IRAK4 Q9NWZ3 1/20 0.39
PDE8B O95263 1/20 0.38
MAPK1 P28482 2/20 0.37
TSHR P16473 1/20 0.37
OGG1 O15527 1/20 0.37
KMT2A Q03164 1/20 0.36
HTR3A P46098 1/20 0.36
HRH4 Q9H3N8 1/20 0.36
KDM4E B2RXH2 2/20 0.36
L3MBTL1 Q9Y468 2/20 0.36
DCPS Q96C86 1/20 0.35
NPY5R Q15761 7/20 0.35
MAPT P10636 3/20 0.35
ALDH1A1 P00352 2/20 0.35
ADRA2A P08913 1/20 0.35
HPGD P15428 1/20 0.35
NPY1R P25929 1/20 0.35
AQP1 P29972 1/20 0.35
NPY2R P49146 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17651921 0.83 GBA1 (0.48) GBA1IRAK4PDE8BTSHRKMT2A
SCHEMBL30918000 0.78 DCPS (0.55) GBA1PDE8BMAPK1TSHROGG1
SCHEMBL4176703 0.78 DCPS (0.55) GBA1PDE8BMAPK1TSHROGG1
SCHEMBL17651892 0.76 KDM4E (0.39) GBA1IRAK4PDE8BMAPK1TSHR
SCHEMBL31579478 0.73 HTR3A (0.56) GBA1MAPK1TSHROGG1HTR3A
SCHEMBL5314315 0.69 DCPS (0.47) PDE8BMAPK1TSHROGG1KMT2A
SCHEMBL21371985 0.67 IRAK4 (0.42) IRAK4KDM4EL3MBTL1ALDH1A1
SCHEMBL26318806 0.66 OGG1 (0.55) GBA1MAPK1TSHROGG1KMT2A
SCHEMBL30507797 0.66 DCPS (0.53) MAPK1TSHRKMT2AHTR3AHRH4
SCHEMBL16822625 0.65 ALDH1A1 (0.47) MAPK1TSHROGG1HTR3AHRH4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12036209-B2 Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides ARVINAS OPERATIONS, INC. (US) 2024-07-16 US disclosed
US-20220331297-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE 4 POLYPEPTIDES ARVINAS OPERATIONS, INC. 2022-10-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12036209-B2 Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides IRAK1, IRAK4, IRAK2 GBA1 3343/4885IRAK4 2/4885PDE8B 2831/4885
US-20220331297-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE 4 POLYPEPTIDES IRAK1, IRAK4, IRAK2 GBA1 3178/4885IRAK4 2/4885PDE8B 2496/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.